Brazil's government contracts attracting Big Pharma; Perez to follow Bonney as Cubist CEO;

@FiercePharma: Top-read special report over the weekend: The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce: India's Ascend sold laxatives to urea creams the #FDA never approved. It's now headed for incineration. Article | Follow @EricPFierce

@CarlyHFierce: Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results. Press release | Follow @CarlyHFierce

> The FDA has approved labeling with abuse-deterrent features for Pfizer's ($PFE) Embeda, an extended-release opioid analgesic. Release

> Government contracts guaranteeing market share in Brazil are starting to attract companies like Roche ($RHHBY), Novartis ($NVS) and Sanofi ($SNY). Report

> Canada will allow for sale more than 40 drugs from three Indian factories recently slapped from import bans now that Health Canada has deemed them "medically necessary." More

> Robert Perez will succeed Michael Bonney at the helm of Cubist Pharmaceuticals ($CBST), effective Jan. 1. More

> Ranbaxy staffers will get a year-long pay-cut shield in the Sun Pharmaceuticals buyout. Report

Medical Device News

@FierceMedDev: Quest and LabCorp won't accept blood samples from suspected patients. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI last week: Boston Scientific wins CE mark for MRI-friendly pacemaker products. Report | Follow @EmilyWFierce

@MichaelGFierce: Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads. FierceDrugDelivery story | Follow @MichaelGFierce

> Nanodevices could be unleashed by DNA-brick self-assembly. Article

> Abbott seals a deal with Zeiss to sell cataract surgery products. Report

Biotech News

@FierceBiotech: PureTech reels in $55M to fund new biotech bets. News | Follow @FierceBiotech

@JohnCFierce: Top 10 Phase III disasters of 2014. Feature | Follow @JohnCFierce

@DamianFierce: ICYMI Friday: Early look at Adaptimmune's cancer immunotherapy data: 1 complete response and 3 partials among 5 patients. Article | Follow @DamianFierce

@EmilyMFierce: TesoRx licenses oral low-T drug to Aspen amid FDA crackdown. Story | Follow @EmilyMFierce

> Cubist CEO Bonney hands over reins as new buyout rumors circulate. Item

> Celgene's $2.6B deal for Crohn's drug pays off with promising PhII. Report

> Genentech pays $150M upfront to partner on NewLink's immuno-oncology drug. Article

CRO News

> Charles River debuts new testing tech for quality control. News

> Big CROs are booming, but can it last? Item

> A glitch in bioequivalence software puts trial results in doubt. More

> INC signs on to help Provectus get its regulatory act together. Article

> PPD pairs off with Sellas to pick up the pipeline pace. Story

Biotech IT News

> Regeneron allies with DNAnexus on 100,000 exomes project. News

> Report: Novo Nordisk to file for IT unit IPO in coming days. Item

> Researchers join forces to build database of 50M genetic variants. More

> Genomics England picks 10 firms for next round of bioinformatics talent contest. Story

> EMA to discuss possible glitch in Thermo bioequivalence software. Article

Animal Health News

> Blaze wins NCI funding for 'tumor paint' after successful dog study. News

> Canadian Government funds Elanco genomics project. Story

> FDA cracks down on Little City Dogs' compounded copies of popular pet meds. Article

> Report: Pork industry group responds to antibiotic documentary with online campaign. More

> Five questions for Aratana CEO Steven St. Peter. Editor's Corner

And Finally... Aspirin boosts schizophrenia treatments, a new study shows. More

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.